www.shcri.com -- According to statistics, the population aged 60 and above in China reached 167.14 million in 2009, accounting for 12.5% of the total population. It rose by 7.25 million (0.5%) compared with that in 2008. In 2009, the population aged above 80 in China reached 18.99 million. The GDP per capita of developed countries with a large aging population is usually USD 5,000-10,000. Among over 70 countries with large aging populations, 36% have the GDP per capita of over USD 10,000. By contrast, the GDP per capita of China was less than USD 4,000 in 2009, which indicates that China has entered the aging society ahead of time.
Senile dementia is a common disease among the elderly. Its incidence rate rises continuously in China in recent years. The major symptoms of senile dementia are the drop of ADL (activities of daily living) ability (e.g. unable to dress oneself and pass urine or stools by oneself), special strange behaviors (e.g. auditory hallucination), cognitive disorder (e.g. unable to retain the memory of major events in one's life and cannot recognize one's spouse, children and even oneself).
In China, senile dementia is much common in the elderly aged over 65. Senile dementia patients account for 4%-5% in this group of people, 10% in the group aged above 75, and 20% in the group aged above 85. It suggests that the incidence rate of senile dementia will increase by one-fold if the age of the elderly rises by 10 years.
According to conservative estimation, the number of senile dementia patients (including Alzheimer's disease as well as vascular dementia, mixed dementia and the senile dementia caused by systemic diseases) totaled 6-8 million, of which less than a half can receive effective treatment.
Cognitive process involves activities like being aware, learning and thinking. The cognitive decline occurs in patients with senile dementia and memory damage. The most common ones are patients with Alzheimer's disease (AD) and vascular dementia (VD). Accordingly, drugs that can improve the cognitive power are generally called nootropics.
There are still many controversies in the nosogenesis and treating method of senile dementia especially AD in the medical circle. Nevertheless, with the advance of the research on the nosogenesis, some progress has been made in the development of drugs. Presently, over ten nootropics developed for the treatment of AD and VD, etc are in the later period of R&D (clinical phase III and the period after that). Five of them are acetylcholinesterase inhibitors under mature research. Other drugs under research have different mechanisms of action. This to some extent reflects that the drug development in this sector is directed towards multi-aspect research aiming at nosogenesis of senile dementia, providing a broader space for the later development of drugs.
In China, misunderstandings over AD exist for a long period. People regard the cognitive decline and memory decrease as normal phenomena of aging. Therefore, for a long period, only brain stimulators (e.g. oxiracetam and piracetam) or antioxidants (e.g. extract of Ginkgo biloba) are adopted for the treatment of AD in China. However, these drugs can only slightly alleviate patient's conditions, displaying extremely limited curative effect. In recent years, with the entry of hot-selling anti-AD drugs from Europe and North America into China, the curative effect of AD is improved considerably. Accordingly, the AD drug market acquires high growth rate. However, the treatment with these drugs demands high expense and the drugs can only control instead of reverse patient's conditions. Hence, the application of these drugs is influenced. Existing AD drugs in domestic hospitals have not been widely accepted by patients. Though the market scale of drugs for senile diseases is large in China, the market scale of therapeutic AD drugs is relatively small.
With the improvement of Chinese people's living standard, common diseases in the elderly gradually catch the close attention of the whole society and accelerate the research and market progress of anti senile dementia drugs. Though Chinese anti senile dementia drug market is in the initial stage, it acquires high growth rate in recent years. In 2009, the scale of Chinese anti senile dementia drug market rose by about 30% YOY to reach CNY 10.40 billion (USD 1.53 billion). It is forecast that this number will maintain the annual growth rate of 20%-30% in recent years.
Through this report, readers can acquire more information:
-Status quo of R&D of anti senile dementia drugs in China
-Competition in Chinese anti senile dementia drug market
-Scale of Chinese anti senile dementia drug market
-Major varieties of anti senile dementia drugs in China and processing of the drugs
-Operation of major producers of anti senile dementia drugs in China
-Prediction on the development of anti senile dementia drugs in China
Following persons are recommended to buy this report:
-Producers of anti senile dementia drugs
-Research institutes concerning Chinese anti senile dementia drugs
-Others concerning Chinese anti senile dementia drugs
Based on the database, Interviews and research methods from China Research and Intelligence, CRI analyzes the development and opportunities in this industry clearly. Contacts: Eileen Gu China Research and Intelligence www.shcri.com Email: email@example.com TEL: 86-21-6852-1029 86-21-5842-6733
Article from articlesbase.com